Cancer Family
Digestive System Neoplasm
CI-CAN-00000012Explore in graph →
Non-malignant4,733 active trials43 approved drugs557 evidence items
Loading cancer entity…
Loading cancer entity…
Cancer Family
CI-CAN-00000012Explore in graph →
Clinical trials
22,059 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT03135652 | Consolidative Radiotherapy for Colorectal Cancer Liver Metastases Receiving Surgery or Radiofrequency Ablation | withdrawn | Phase 2 | 0 | Union Hospital, Tongji Medical College, Huazhong University of Science and TechnologyOTHER | 1 | Jan 3, 2024 | clinicaltrials |
| NCT03193814 | Safety and Efficacy Study of Chemotherapy Plus Apatinib as Second-line Therapy in Metastatic Colorectal Cancer(XHZL) | withdrawn | Phase 2 | 0 | Union Hospital, Tongji Medical College, Huazhong University of Science and Technology |
| 0 |
| Jan 3, 2024 |
| clinicaltrials |
| NCT00846313 | Can Malnutrition be Prevented in Patient With Colorectal Cancer Stage Dukes D?(ColErn) | withdrawn | N/A | 0 | Norwegian University of Science and TechnologyOTHER | 0 | Dec 29, 2023 | clinicaltrials |
| NCT04870034 | Binimetinib and Palbociclib Before Surgery for the Treatment of Operable KRAS-Positive Lung, Colorectal, or Pancreatic Cancer | withdrawn | Early Phase 1 | 0 | Roswell Park Cancer InstituteOTHER | 1 | Dec 22, 2023 | clinicaltrials |
| NCT05465590 | A Phase 1 Study to Evaluate Paclitaxel Conjugated CXC Receptor 4 Antagonist (MB1707) in Patients With Advanced Cancer | withdrawn | Early Phase 1 | 0 | Mainline Biosciences, Inc.INDUSTRY | 0 | Dec 21, 2023 | clinicaltrials |
| NCT05702385 | Clinical Utility Study for Exo-PDAC | withdrawn | N/A | 0 | Qure Healthcare, LLCINDUSTRY | 1 | Dec 7, 2023 | clinicaltrials |
| NCT02017366 | Design of the EFECTS Trial(EFECTS) | withdrawn | N/A | 0 | University Hospital, GasthuisbergOTHER | 1 | Dec 6, 2023 | clinicaltrials |
| NCT02519140 | Assessing How the Viscosity of Submucosal Gel Injections Helps With Endoscopic Mucosal Resections | withdrawn | Phase 3 | 0 | Antonios LikourezosOTHER | 1 | Dec 4, 2023 | clinicaltrials |
| NCT05641922 | Safety and Effectiveness of BioTraceIO 360 for Planning, Monitoring and Assessment of Liver Tissue Ablation Procedures (PANORAMA2)(PANORAMA2) | withdrawn | N/A | 0 | Techsomed Medical Technologies LTDINDUSTRY | 0 | Nov 27, 2023 | clinicaltrials |
| NCT04835987 | Evaluation of the Autonomic Nervous System in Patients Undergoing Esophagectomy for Cancer(PROSNACO) | withdrawn | — | 0 | Centre Hospitalier Universitaire de Saint EtienneOTHER | 1 | Nov 24, 2023 | clinicaltrials |
| NCT04602117 | ISPY-P1.01:Evaluating the Safety of Weekly Paclitaxel With Trastuzumab Duocarmazine (SYD985) in Patients With Metastatic Cancer | withdrawn | Phase 1 | 0 | QuantumLeap Healthcare CollaborativeOTHER | 1 | Nov 18, 2023 | clinicaltrials |
| NCT05111314 | Comparison of Hepatic Intraarterial Versus Systemic Intravenous 68Ga-PSMA PET/CT for Detection of Hepatocellular Carcinoma | withdrawn | Early Phase 1 | 0 | Mayo ClinicOTHER | 1 | Nov 7, 2023 | clinicaltrials |
| NCT04054752 | Vaccine Response With NT-I7 | withdrawn | Phase 1 | 0 | National Cancer Institute (NCI)NIH | 1 | Nov 2, 2023 | clinicaltrials |
| NCT06017323 | Proglumide With Gemcitabine and Nab-Paclitaxel in PatientsWith Metastatic Pancreatic Ductal Adenocarcinoma(ProglumidePanc) | withdrawn | Phase 1 | 0 | Georgetown UniversityOTHER | 1 | Oct 25, 2023 | clinicaltrials |
| NCT06090318 | Milademetan in Combination With Atezolizumab in Patients With Advanced Solid Tumors With CDKN2A Loss | withdrawn | Phase 1 / Phase 2 | 0 | Rain Oncology IncINDUSTRY | 0 | Oct 19, 2023 | clinicaltrials |
| NCT05821582 | Study SBX-01-101: A Stool Collection Study in Colorectal Cancer (CRC) Patients Treated With Irinotecan-Based Regimens | withdrawn | — | 0 | Sanguine BiosciencesINDUSTRY | 1 | Oct 12, 2023 | clinicaltrials |
| NCT04795869 | Brentuximab Vedotin and Pembrolizumab in Treating Patients With Recurrent Peripheral T-Cell Lymphoma | withdrawn | Phase 2 | 0 | Northwestern UniversityOTHER | 1 | Oct 10, 2023 | clinicaltrials |
| NCT05092750 | Magnetic Particle-ICG Lymph Node Mapping in Colorectal Cancer | withdrawn | Phase 1 / Phase 2 | 0 | M.D. Anderson Cancer CenterOTHER | 0 | Sep 28, 2023 | clinicaltrials |
| NCT02716688 | S-1 and Radiotherapy for Elderly Esophageal Cancer Patients | withdrawn | Phase 2 | 0 | Zhejiang Provincial People's HospitalOTHER | 1 | Sep 22, 2023 | clinicaltrials |
| NCT02535988 | Abscopal Effect for Metastatic Colorectal Cancer | withdrawn | Phase 2 | 0 | Zhejiang Provincial People's HospitalOTHER | 0 | Sep 21, 2023 | clinicaltrials |
| NCT03991104 | SOX-based CRT for Esophageal Cancer. | withdrawn | Phase 1 / Phase 2 | 0 | Zhejiang Provincial People's HospitalOTHER | 1 | Sep 21, 2023 | clinicaltrials |
| NCT01023984 | Transanal Endoscopic Microsurgery Versus Endoscopic Submucosal Dissection For Large Rectal Adenomas(TEMENDO) | withdrawn | Phase 4 | 0 | European Association for Endoscopic SurgeryOTHER | 1 | Sep 8, 2023 | clinicaltrials |
| NCT05412706 | Niraparib Maintenance Treatment in mCRC With a Partial o Complete Response After Oxaliplatin-based Induction Therapy(Bohème) | withdrawn | Phase 2 | 0 | Ospedale Policlinico San MartinoOTHER | 0 | Sep 8, 2023 | clinicaltrials |
| NCT05043987 | Dose Escalation and Expansion Study of CPO102, an Anti-claudin 18.2 ADC in Patients With Advanced Cancers | withdrawn | Phase 1 | 0 | Conjupro Biotherapeutics, Inc.INDUSTRY | 0 | Sep 7, 2023 | clinicaltrials |
| NCT05379907 | Observational Study of ctDNA in Resectable and Borderline Resectable Pancreatic Cancer | withdrawn | — | 0 | Inova Health Care ServicesOTHER | 1 | Sep 6, 2023 | clinicaltrials |
| NCT05510427 | Phase Ib Trial of Infigratinib In Combination With Atezolizumab And Bevacizumab for The Second-Line Treatment of Advanced Cholangiocarcinoma With FGFR2 Fusion/Amplification | withdrawn | Phase 1 | 0 | M.D. Anderson Cancer CenterOTHER | 0 | Aug 15, 2023 | clinicaltrials |
| NCT04591028 | A Study to Evaluate Indocyanine Green Lymphangiography to Improve Lymphadenectomy in Gastric Cancer Patients | withdrawn | Phase 4 | 0 | Mayo ClinicOTHER | 1 | Jul 19, 2023 | clinicaltrials |
| NCT05951842 | Anesthesia, TIVA, Balanced Anesthesia, NK Cell | withdrawn | N/A | 0 | Gangnam Severance HospitalOTHER | 0 | Jul 19, 2023 | clinicaltrials |
| NCT05109052 | Trial of PXS-5505 Combined With First Line Atezolizumab Plus Bevacizumab For Treating Patients With Unresectable Hepatocellular Carcinoma | withdrawn | Phase 1 / Phase 2 | 0 | University of RochesterOTHER | 1 | Jul 13, 2023 | clinicaltrials |
| NCT03722498 | Phase Ⅱ Study of HAIC of FOLFOX vs. Sorafenib in HCC Refractory to TACE | withdrawn | Phase 2 | 0 | Sun Yat-sen UniversityOTHER | 1 | Jul 11, 2023 | clinicaltrials |
| NCT05216120 | Pemigatinib in Subjects With Adenosquamous Carcinoma of the Pancreas | withdrawn | Phase 2 | 0 | HonorHealth Research InstituteOTHER | 1 | Jul 3, 2023 | clinicaltrials |
| NCT02515513 | The Role of Muscle Cachexia in Pancreatic Cancer | withdrawn | N/A | 0 | University of FloridaOTHER | 1 | Jun 28, 2023 | clinicaltrials |
| NCT05431582 | Phase I Study of ZN-c3 and Bevacizumab ± Pembrolizumab in Metastatic CCNE1 Amplified and TP53 Mutant Solid Tumors | withdrawn | Phase 1 | 0 | M.D. Anderson Cancer CenterOTHER | 0 | Jun 15, 2023 | clinicaltrials |
| NCT05411679 | EP0057 in Combination With Olaparib in Relapsed Advanced Gastric Cancer and Small Cell Lung Cancer | withdrawn | Phase 2 | 0 | Ellipses PharmaINDUSTRY | 3 | Jun 12, 2023 | clinicaltrials |
| NCT05582031 | Regorafenib With Tislelizumab in Patients With Selected Mismatch Repair-Proficient/Microsatellite Stable Cancers(REFIT-MSS) | withdrawn | Phase 2 | 0 | Translational Research in OncologyOTHER | 0 | Jun 7, 2023 | clinicaltrials |
| NCT05886257 | Candonilimab Plus Bevacizumab for Patients With Advanced HCC Who Progressed on A+T | withdrawn | Phase 2 | 0 | Shi MingOTHER | 1 | Jun 2, 2023 | clinicaltrials |
| NCT02344810 | C-Met Inhibitor AMG 337, Oxaliplatin, Leucovorin Calcium, and Fluorouracil in Treating Patients With Advanced Stomach or Esophageal Cancer | withdrawn | Phase 1 / Phase 2 | 0 | Eastern Cooperative Oncology GroupNETWORK | 1 | May 25, 2023 | clinicaltrials |
| NCT04535492 | Technology-Based Cancer Screening Intervention | withdrawn | N/A | 0 | Medical University of South CarolinaOTHER | 1 | May 11, 2023 | clinicaltrials |
| NCT05251038 | Study of Sotorasib Combined With Chemotherapy for Second Line Treatment of Pancreas Cancer | withdrawn | Phase 1 / Phase 2 | 0 | Devalingam MahalingamOTHER | 1 | May 11, 2023 | clinicaltrials |
| NCT02174575 | Anesthetic Agents and Acute Kidney Injury After Liver Resection Surgery | withdrawn | Phase 4 | 0 | Tokyo Medical and Dental UniversityOTHER | 1 | May 3, 2023 | clinicaltrials |
| NCT03999658 | A Study of STI-3031 (an Anti-PD-L1 Antibody) in Patients With Selected Relapsed/Refractory Malignancies | withdrawn | Phase 2 | 0 | Sorrento Therapeutics, Inc.INDUSTRY | 0 | May 1, 2023 | clinicaltrials |
| NCT02682485 | Serial Endoscopic Surveillance & Direct Topical Antibiotics to Define the Role of Microbes in Anastomotic Healing(SES-DTA) | withdrawn | Phase 2 | 0 | University of ChicagoOTHER | 0 | Apr 26, 2023 | clinicaltrials |
| NCT05246943 | The Correlation of a D-dimer Testing Protocol With Venous Thromboembolism in Surgical Colorectal Patients | withdrawn | — | 0 | The University of Texas Medical Branch, GalvestonOTHER | 0 | Apr 25, 2023 | clinicaltrials |
| NCT04852367 | PanDox: Targeted Doxorubicin in Pancreatic Tumours(PanDox) | withdrawn | Phase 1 | 0 | University of OxfordOTHER | 1 | Apr 12, 2023 | clinicaltrials |
| NCT04811833 | Gastrointestinal Anastomosis Using MonoPlus® Suture(GASTROMO) | withdrawn | — | 0 | Aesculap AGINDUSTRY | 1 | Apr 5, 2023 | clinicaltrials |
| NCT05183295 | Medical Food for the Dietary Management of Metastatic Colorectal Cancer | withdrawn | N/A | 0 | Faeth TherapeuticsINDUSTRY | 0 | Apr 3, 2023 | clinicaltrials |
| NCT00430313 | Effects of Acupoint Electro-stimulation on Preventing Nausea and Vomiting Induced by Cisplatin or Oxaliplatin | withdrawn | N/A | 0 | M.D. Anderson Cancer CenterOTHER | 0 | Mar 29, 2023 | clinicaltrials |
Data updated 23 days agoSource updated Jan 3, 2024source: clinicaltrials